Idaho Bills

Adds to existing law to establish the Medical Advanced Healing Act.

RS33592C1 / H0899 The Trump Administration’s 2024 National Defense Authorization Act (NDAA) allows states to begin studying rapid-acting therapies like neuroplastogens to treat conditions such as Post Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury (TBI). This is because recent studies have shown neuroplastogens have the potential for more effective treatment of mental health conditions like anxiety and depression, trauma, and addiction. States like Indiana, Arizona, New Jersey, Mississippi, and Texas have begun the process of enacting pilot programs to study the effectiveness of these treatments. Particular focus is on the United States veteran population, which is experiencing an average of 22 suicides a day from returning soldiers whose serious mental health conditions are not being effectively treated by traditional medications. U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy stated the Trump administration’s goal is to make neuroplastogens widely available as soon as possible in the United States. The heads of the U.S. Department of Veterans Affairs (VA), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) are also looking at the potential benefits of neuroplastogens. This legislation would create a revenue-neutral pilot program for Idaho to join in this effort.